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Economic imPact of a Smoking cESSation PRogRam in mExico: 
EnRolling EmPloyEES and EmPloyERS
Huicochea-Bartelt J.L., Muciño-Ortega E., Hernandez-Reyes F.C.
Pfizer S.A. de C.V., Ciudad de México, Mexico
BAckground: Smoking costs at work affect both employers and employees. These 
costs are a result of a combined loss of productivity, time off work due to illness, 
smoking breaks and increasing insurance costs. oBjectives: This study aims to 
evaluate the economical impact of a 12 week smoking cessation program with 
varenicline from an employer perspective in a medium size Mexican-Corporate set-
ting. Methods: A decision tree was built in order to estimate the two endpoints of 
the program: resource used in terms of costs and productivity gains in labor hours, 
in a three year horizon. Smokers enrolling in the program were assumed to be the 
proportion of people who reported being very much indeed interested on quitting 
smoking in a 2005 UK survey (27%). A promotional cost of a 12 week combo-pack of 
varenicline was provided by the manufacturer. A literature review was performed 
in order to obtain smoking specific data of the country and response rates. Labor 
costs were retrieved from the Mexican National Institute of Statistics and Geography 
(INEGI). A base scenario of a medium sized company (250 employees) was assumed 
to show the potential benefits of the program. results: Assuming a 250 employ-
ees company and a shared proportion of 50% of the costs of the program between 
employees and employers, companies would have to invest US$178 per employee 
only at the first year, and have potential savings of US$228 for each of them after 
3 years. At the same circumstances the net productivity gains per programme 
participant would be in an amount of 70.8 hours. conclusions: This research 
showed that if mexican employers invest in a smoking cessation program, signifi-
cant productivity gains and savings could be reached in a 3 year horizon.
RESPiRatoRy-RElatEd diSoRdERS – Patient-Reported outcomes & Patient 
Preference Studies
PRS43
thE RElationShiP BEtwEEn tREatmEnt SatiSfaction and adhEREncE in 
coPd PatiEntS in 5 countRiES
Vietri J.1, Isherwood G.2
1Kantar Health, Milan, Italy, 2Kantar Health, Epsom, Surrey, UK
oBjectives: To assess the relationship between treatment satisfaction and adherence 
in chronic obstructive pulmonary disease (COPD) in European patients, and whether the 
strength of this relationship varies according to country. Methods: Data were taken 
from the 5EU (France, Germany, Italy, Spain, and UK) 2011 National Health and Wellness 
Survey (NHWS), a cross-sectional survey representative of the total adult populations 
in each 5EU country. The current analysis included all respondents taking one or two 
treatments for COPD (including chronic bronchitis, COPD, and emphysema; n= 914). 
Satisfaction with medication was measured using a single item per treatment, and 
averaged for respondents taking two treatments. Adherence was measured using a sin-
gle 4-item Morisky Medication Adherence Scale (MMAS) for all COPD treatments used. 
Spearman correlations were used to assess the relationship when adherence was consid-
ered as an ordinal variable, and binary logistic regressions were used to assess the rela-
tionship between the two constructs when adherence was dichotomized. Regressions 
included age and gender as covariates. results: Bivariate correlations demonstrated 
a modest relationship between satisfaction and adherence within COPD patients across 
the five countries rs = .133, p< 0.001). The strength of this relationship ranged from a low 
of rs = 0.05 in France (p = 0.60) to a high of rs= .37 in Spain (p< 0.001). A significant interac-
tion between country and satisfaction confirmed that the relationship varied by country. 
When the relationship was examined within each country, satisfaction was a signifi-
cant predictor of adherence only in Spain and the UK (both p< 0.05). conclusions: 
Mean level of adherence to COPD treatments differed across European countries. Higher 
satisfaction was generally associated with greater adherence, but the strength of this 
relationship varied. Ensuring treatments are satisfactory to the patient may promote 
greater adherence, but the strength of the impact is likely to vary across populations.
PRS44
factoRS RElatEd to adhEREncE aftER a multifactoRial intERvEntion 
to imPRovE it in PatiEntS with chRonic oBStRuctivE PulmonaRy 
diSEaSE (coPd). icEPoc Study
Leiva-Fernandez F.1, Leiva-Fernandez J.2, Prados-Torres D.1, García-Ruiz A.J.3, Barnestein-
Fonseca P.1
1Distrito Sanitario Málaga (SAS), Málaga, Spain, 2Area Sanitaria Málaga Este-Axarquia, Málaga, 
Spain, 3Malaga University, Malaga, Spain
oBjectives: To identify factors related to adherence after a multifactorial interven-
tion in patients with COPD. Methods: Design: Randomized Controlled Trial (ISRCTN 
15106246) Patients: 146 subjects randomly allocated (random blocks of 4 patients) in 
two groups (intervention group-IG, control group-CG). Intervention components: 1)
Motivational aspects: beliefs-behaviour about COPD (group and individual interviews); 
2) Cognitive aspects: information about illness; and 3) Skills: inhaling techniques train-
ing. Follow-up: 1 year, 5 visits/group. Primary Outcome: adherence (pill/doses count); 
Secondary Outcomes: functional status (spirometry), quality of life (Saint George 
Respiratory Questionnaire-SGRQ); Independent variables: intervention, age, sex, edu-
cational level, comorbidity, COPD severity stage (SEPAR guidelines), prescribed medi-
cation. Statistical analysis: Four partial logistic regression models, fixed- and random 
effects estimation, were carried out, a final model was built considering them. Statistical 
packages SPSS 15.0 and Stata 11.1. results: Predominance of males (91.8%), mean 
age 69.08 years (CI95%,67.58-70.44); low cultural level (78.1%), 32.2% current smokers 
(62.84 pack-years [CI95%,55.34-70.34]), Body Mass Index 30.78 kg/m2 (CI95%,28.78-
32.78), 81.2% mild-moderate severity stage, predominance of obstructive respiratory 
pattern; FEV1 (mean)= 67.58% (CI95%,64.58-71.08), 0.87 exacerbations/year [CI95%, 0.68-
1.06]. Pharmacological treatment: inhaled-beta2-adrenergic (80.1%); inhaled-anticho-
linergic (77.4%); inhaled-corticosteroids (70.5%); mucolitycs (11.6%); xanthine (8.2%); 
oxygen therapy (4.8%); oral-corticosteroids (0.7%). Adherence was 41% (41.2CG/40.8IG). 
oBjectives: To analyze the costs of macrolides use compared to cephalosporines 
for treatment of Acute Bacterial Sinusitis (ABSs) in the era of increasing resist-
ance to Streptococcus pneumoniae. Methods: We used a decision analysis model 
(TreeAge Pro 2013) to perform a cost-minimization and sensitivity analysis to 
determine what level of macrolide resistance in a community would trigger cepha-
losporine use. Costs and clinical outcomes of ABSs were extracted from a system-
atic review of the literature and official local databases. Clinical response was 
derived from prospective clinical trials, investigations and from clinical experts 
experience, were we had ≤ 1 source. results: We have found that the mean cost 
of empirical treatment with macrolides for ABSs was 79 EUR when community 
S. pneumoniae resistance was at 0%; 77 EUR at 10%; 82 EUR at 20% and 88 EUR at 
30%. Cephalosporines were found to be cost-minimizing when the prevalence of 
macrolide resistance to S. pneumoniae exceeded 15%. Sensitivity analysis variables 
that had a significant impact on our cost-minimization threshold included propor-
tion of macrolide resistance to S. pneumoniae, cost of antibiotics and probabilities 
of clinical cure with antibiotics. conclusions: We believe we have performed 
the first cost-based model and sensitivity analysis to determine what level of 
macrolide resistance in the community could trigger a switch of empirical therapy 
for ABSs from macrolides to cephalosporines in Slovakia. Our investigation is 
to our knowledge also locally the first to employ decision analysis to explore 
the relationship between antimicrobial resistance and clinical decision making 
in ABSs. From a payer perspective, cephalosporines appears to be a reasonable 
alternative to macrolides for empirical treatment of ABSs, especially given the 
current prevalence of macrolides resistance among S. pneumoniae in community 
that reached 30% level, nationwide.
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Economic Evaluation of mandiBulaR advancEmEnt dEvicE to tREat 
oBStRuctivE SlEEP aPnEa
Giannopoulou A.1, Burgers L.T.1, van Bruggen M.P.B.2, de Vries N.3, Redekop W.K.1,  
Rijnsburger A.1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Philips Research Europe, 
Eindhoven, The Netherlands, 3St. Lucas Andreas Hospital, Amsterdam, The Netherlands
oBjectives: In the treatment of obstructive sleep apnea/hyoponea syndrome 
(OSAHS) moderate patients are primarily offered Continuous Positive Airway 
Pressure (CPAP). This study aims to assess the cost-effectiveness of mandibular 
advancement device (MAD), a commonly suggested alternative, as compared to 
CPAP for moderate OSAHS patients in The Netherlands. Methods: The prognosis 
of a hypothetical cohort of 50-year-old patients with moderate OSAHS was simu-
lated with a Markov model to estimate the costs and quality-adjusted life-years 
(QALYs) for both CPAP and MAD. A distinctive factor incorporated in the model 
was switch of therapy. All input parameters, including the risks of experiencing 
myocardial infarction, stroke and motor vehicle crashes (MVC) were based on lit-
erature and clinical expert opinion. Costs and effects were estimated over a 5-year 
time horizon using a health care provider perspective and were discounted at a 
rate of 4% and 1.5%, respectively. Robustness of the results was investigated with 
several sensitivity and scenario analyses. results: Compared with CPAP, MAD 
is less expensive (€ 4,511 vs. € 5,302) and only slightly less effective (3.44 vs. 3.49 
QALYs) resulting in an incremental cost-effectiveness ratio (ICER) of € 15,393 saved 
per QALY lost. The most influential parameter was the cost of MAD device and its 
titration. Quality-of-life values, compliance rates, costs and the probabilities of 
switching treatment, cardiovascular events and MVC were varied in the scenario 
analyses. Under the majority of the scenarios MAD remained less cost-effective 
compared to CPAP. conclusions: Over a 5-year time horizon, MAD therapy may 
be considered not cost-effective in the treatment of moderate OSAHS patients in 
The Netherlands. Further research on the impact of both treatments on long-term 
risks and improvement in the quality of life is required. Similarly, more long-term 
studies using a uniform compliance definition are needed to inform future cost-
effectiveness analyses.
PRS41
intEgRating thE long-tERm hEalth BuRdEn of oRal coRticoStERoidS 
in thE coSt-EffEctivEnESS of omalizumaB
Faria R., McKenna C.
University of York, York, UK
oBjectives: Omalizumab offers an alternative to maintenance oral corticosteroids 
(OCS) in the treatment of severe persistent asthma. Despite widespread recognition 
of the adverse effects from OCS, there is little quantitative evidence on their health 
burden or costs. Failing to account for the adverse effects of OCS may underestimate 
the cost-effectiveness of innovative steroid-sparing medicines such as omalizumab. 
This study aims to explore the possibilities for integrating evidence on the burden of 
OCS in cost-effectiveness analysis using omalizumab as a case study. Methods: A 
model was developed to evaluate the long-term cost-effectiveness of omalizumab in 
patients requiring maintenance OCS. Costs were from a health service perspective 
and outcomes were measured as quality-adjusted life years (QALYs). The burden from 
maintenance use of OCS was quantified with population-based approach, with a deci-
sion model and with threshold analysis. results: The incremental cost-effectiveness 
ratio (ICER) was £37,987 per QALY gained, which is above conventional thresholds used 
in the UK. Threshold analysis showed that the annual health losses from maintenance 
use of oral corticosteroids would need to be 0.12 QALYs per year. This is double the 
quantifiable health losses with the population-based approach and with the decision 
model and 10% of the health gains achieved with omalizumab. conclusions: The 
burden from maintenance OCS can be integrated in cost-effectiveness analysis but 
the extent to which these estimates account for their full impact on health depends 
on the approach used and underlying assumptions. The challenges arise from sparse 
randomised evidence, time lag in the adverse effects and unclear relationship between 
risk and long-term steroid load. These are empirical questions which can be answered 
with further research. Such research would be valuable not only for decision making in 
severe asthma but also for other conditions treated with maintenance OCS.
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oBjectives: Adherence and health-related quality of life (HRQoL) are two impor-
tant indicators in determining success of drug treatments. Although medication 
adherence and HRQoL have been studied intensively, less is known about the asso-
ciation of these factors. This research aims to undertake a systematic review of the 
published literature on the relationship of medication adherence and HRQoL in 
patients with chronic obstructive pulmonary disease (COPD). No comprehensive 
review has been published in this topic so far. Methods: Peer-reviewed English-
language articles that examined the relationship between adherence/compliance/
persistence to medication and HRQoL in COPD were identified through database 
(Medline, EMBASE) searches. Reports until April 2013 were screened. Papers related 
to oxygen therapy were excluded. results: Of the 243 papers reviewed, eight stud-
ies met the inclusion criteria and were analyzed in our systematic review. Evidence 
suggests that relationship between medication adherence and HRQoL is dual. Non-
adherence does not have a clear negative impact on HRQoL. Adherence to medica-
tion may affect HRQoL due to more factors, such as effectiveness/efficacy and side 
effects of the medication, daily life limitation and social stigmatization caused by 
the therapy. Effect of non-adherence on HRQoL can be derived from the resultant 
of these factors. Nevertheless, HRQoL may also influence patients’ drug use; poor 
or good HRQoL may trigger non-adherence. Relationship between adherence and 
HRQoL may differ depend on the duration of the previous therapy (as therapy in 
newly diagnosed COPD patients may improve HRQoL more than in patients treated 
previously for longer durations) and on the study design (cross-sectional versus 
longitudinal follow-up study) as well. conclusions: Association of medication 
adherence and HRQoL is multiple. Results from previous studies are limited. Further 
scientific evaluations are needed to better understand the dynamics between these 
factors. Such information would be critically important and needs to be considered 
when integrating adherence into health-economic evaluations.
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EStimation of gEnERic utilitiES in SPaniSh chRonic oBStRuctivE 
PulmonaRy diSEaSE PatiEntS
Miravitlles M.1, Huerta A.2, Villa G.2, Forne C.3, Cuesta M.3, Brosa M.3, Crespo C.3
1Hospital Universitari Vall d’ Hebrón, Barcelona, Spain, 2GlaxoSmithKline, Madrid, Spain, 
3Oblikue Consulting, Barcelona, Spain
oBjectives: Chronic obstructive pulmonary disease (COPD) is a major public health 
problem and one of the leading causes of chronic morbidity and mortality worldwide. 
This study aims at determining generic utilities for Spanish COPD patients stratified by 
international guidelines GOLD 2006 (airflow limitation) and GOLD 2013 (airflow limita-
tion, exacerbation history and symptoms), and Spanish guidelines GesEPOC (clinical 
phenotypes). Methods: Multicentre, observational, cross-sectional study, carried out 
in 15 Pulmonology Spanish public services, including patients aged 40+, diagnosed with 
COPD, who have not experienced an exacerbation in the previous 2 months and receiv-
ing pharmacological treatment for COPD. Utilities were derived from EQ-5D-3L scores. 
Medians, means and standard deviations (SD) were computed for groups of patients 
based on GOLD 2006, GOLD 2013 and GesEPOC classifications. Differences in median 
utilities between groups were assessed by means of Kruskal-Wallis tests. Post-hoc pair-
wise comparisons were based on Wilcoxon tests (Bonferroni-adjusted). results: A 
total of 346 patients were included in the analysis. Statistically significant median dif-
ferences in utilities by groups of patients were found. GOLD 2006: moderate (n= 135, 
median= 0.87, mean= 0.81, SD= 0.22); severe (n= 145, median= 0.80, mean= 0.71, SD= 0.29); 
very severe (n= 66, median= 0.67, mean= 0.57, SD= 0.35); (p< 0.001). All pair-wise compari-
sons were statistically significant (p< 0.001). GOLD 2013: group A (n= 28, median= 0.98, 
mean= 0.94, SD= 0.06); group B (n= 66, median= 0.87, mean= 0.80, SD= 0.22); group C (n= 30, 
median= 0.98, mean= 0.87, SD= 0.24); group D (n= 222, median= 0.74, mean= 0.66, SD= 0.30); 
(p< 0.001). All pair-wise comparisons were statistically significant (p< 0.002), except-
ing groups A and C comparison. GesEPOC: (A) non-exacerbator (n= 215, median= 0.84, 
mean= 0.78, SD= 0.23); (B) overlap COPD-asthma (n= 21, median= 0.80, mean= 0.80, 
SD= 0.19); (C) exacerbator with emphysema (n= 46, median= 0.74, mean= 0.59, SD= 0.40); 
(D) exacerbator with chronic bronchitis (n= 64, median= 0.74, mean= 0.62, SD= 0.33); 
(p< 0.001). Pair-wise comparisons between phenotypes A and C (p< 0.002) and pheno-
types A and D (p< 0.001) were statistically significant. conclusions: Generic utilities 
are associated with airflow limitation, exacerbation history, symptoms and clinical 
phenotypes in a sample of Spanish COPD patients.
PRS49
PatiEnt-REPoRtEd outcomE (PRo) claimS in PRoductS aPPRovEd foR 
chRonic oBStRuctivE PulmonaRy diSEaSES (coPd) in EuRoPE and thE 
unitEd StatES
Caron M., Perrier L.L., Acquadro C.
Mapi Research Trust, Lyon, France
oBjectives: 1) To identify COPD products approved with a Patient-Reported Outcome 
(PRO) labeling claim in Europe and the USA, and 2) to list the differences found in 
Europe vs. the USA in terms of products and labeling. Methods: The search was 
performed on the FDA- and EMA-approved medicinal product labels and medical 
reviews/scientific discussions (from January 1995 - February 2013 inclusive). results: 
A total of 25 COPD products were retrieved: 11 were approved by the EMA and 14 
by the FDA. Only three INN were approved by both agencies (aclidinium bromide, 
indacaterol, and roflumilast), representing 11 products (EMA, n= 8; FDA, n= 3). Out of 
the 25 products approved, 15 have a PRO claim (EMA, n= 8; FDA, n= 7). When focusing 
on the INN approved by both agencies, the review showed that the FDA and the EMA 
agreed on the granting of a PRO claim (i.e., “yes” for aclidinium bromide and inda-
caterol, and “no” for roflumilast). The FDA and the EMA reviewed the same clinical 
studies. However, the labeling text differs between the agencies. The FDA label of acli-
dinium bromide does not provide any mention of results measured by the St. George’s 
Respiratory Questionnaire (SGRQ) and the Transition Dyspnoea Index (TDI), while the 
EMA label does. As for indacaterol, the FDA label does not mention any TDI results, 
while the EMA label does. Reasons for these discrepancies are found in the FDA medi-
cal reviews. The TDI has been assessed as inadequate for use as a CT endpoint. As for 
the SGRQ, the results met the threshold of clinically meaningful improvement in only 
Both groups were similar at baseline. Drop out was 28.8%. Intention to treat analysis. 
Adherence increased significantly in IG (p= 0.046), NNT= 6.37 (CI95%,3.25-142.8). Factors 
related to adherence: intervention (OR= 1.88, CI95%,1.01-3.52), number of exacerbation 
(OR= 0.66,CI95%,0.48-0.91), number of visits to health centre (OR= 0.93,CI95%,0.87-1.00), 
severity (OR= 0.677,CI95%,0.43-1.04), number of devices (OR= 2.4,CI95%,1.09-5.30), SGRQ-
Activity scale (OR= 0.978,CI95%,0.95-1.00), SGRQ-Impact scale (OR= 1.03,CI95%,1.00-1.06), 
inhaled-beta2-adrenérgic (OR= 0.16, CI95%,0.059-0.43), xanthine (OR= 0.199, CI95%,0.05-
0.77). Rho coefficient= 6.07x10-6 (p= 0.498). conclusions: The more adherent patient 
was that who showed a lower number of visits to health centre, exacerbations, number 
of devices, level of severity, and impact on daily activities but with higher disease impact. 
The beta-2-adrenergic and xanthine treatment are associated with no adherence.
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how do PatiEntS with chRonic oBStRuctivE PulmonaRy diSEaSE 
(coPd) uSE thEiR inhalERS? common miStakES. tEcEPoc Study
Leiva-Fernandez F.1, Leiva-Fernandez J.2, Porcel-Martin C.1, Prados-Torres D.1, García-Ruiz 
A.J.3, Barnestein-Fonseca P.1
1Distrito Sanitario Málaga (SAS), Málaga, Spain, 2Area Sanitaria Málaga Este-Axarquia, Málaga, 
Spain, 3Malaga University, Malaga, Spain
oBjectives: To test the inhaler use in COPD patients. Frequent mistakes. Methods: 
Design: Cross-sectional study at the beginning of a Multicenter patients’ prefer-
ence trial (ISRCTN15106246) Patients: 465 COPD patients from 9 health care centres, 
with inhaled treatment, written consent. Non-probabilistic consecutive sampling. 
Variables: inhaler devices, performance of correct inhalation technique, type of mis-
takes. Age, sex, Inhalatory pick flow, COPD severity stage, prescribed medication. 
Basal dyspnea index (BDI). Statistical analysis: Mean, frequency. 95% confidence inter-
val. results: Predominance of males (91.4%), mean age 69.8 years (CI95%,69.00-70.59); 
FEV1(mean)= 55.91%(IC95:53.62-58.2), mixed respiratory pattern (65.9%). Severity stage: 
15.7% mild, 44.1% Moderate, 40.3% Severe. Pharmacological treatment: inhaled-beta2-
adrenergic (88.8%); inhaled-corticosteroids (76.7%); inhaled-anticholinergic (70.7%); 
mucolitycs (19.4%); xanthine (7.3%); oral-corticosteroids (1.3%). BDI: grade 2. Inhalation 
technique: 84.9% had received instruction about inhalation techniques (48.6% from neu-
mologist, 42.1% from general practitioner). The instruction was an explanation without 
device (59.6%). 67.3% of patients used Handihaler, 54.8% Accuhaler, 31.8% Turbuhaler, 
26.9% pressurised metered dose inhaler (pMDI). The 91.3% of patients performed an 
incorrect inhalation technique with handihaler, 89.5% with Turbuhaler, 85.6% with 
Accuhaler and 91.7% with pMDI. The most common mistakes in all devices were related 
to the action consist on: emptying or almost emptying the lungs before activating the 
spray (79.8%) and holding breath for at least 8-10 seconds or for as long as possible 
when inhalation is complete (69.5%). The most common mistakes per device were 
related to: repeating the inhalation with Handihaler (10%), Loading the dispenser cor-
rectly in Accuhaler (8.2%) or Turbuhaler (16.6%) and hand-breath coordination in pMDI 
(52.8%). conclusions: A high percentage of patients with COPD performed an incor-
rect inhalation technique although they had been received instruction about this. The 
most common mistakes are more related to the patient’s attitude than to the type of 
device.
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tEcEPoc Study. how to imPRovE thE inhalation tEchniquES in PatiEnt 
with coPd. thE influEncE of PREfEREncES
Leiva-Fernandez F.1, Leiva-Fernandez J.2, Porcel-Martin E.1, Vazquez-Alarcon R.1, Martos-
Crespo F.3, Barnestein-Fonseca P.1
1Distrito Sanitario Málaga (SAS), Málaga, Spain, 2Area Sanitaria Málaga Este-Axarquia, Málaga, 
Spain, 3Málaga University, Málaga, Spain
oBjectives: to test the efficacy of two educational interventions to improve the 
inhalation techniques in patients with COPD and the influence of patient’ prefer-
ence. Methods: Design: Multicenter patients’ preference trial or comprehensive 
cohort design ISRCTN15106246. Patients: 465 COPD patients (to detect a difference 
between groups of 25%, 80% statistical power, 95% confidence level, 40% expected 
losses), with inhaled treatment, written consent. Non-probabilistic consecutive sam-
pling. Allocation: Patients without strong preferences for a treatment are randomised: 
RCT group (block randomization), and those with strong preferences are given their 
choice: PPS group. Variables: Primary outcomes: Performance of correct inhalation tech-
nique. Secondary outcomes: Pick flow, dyspnea (Baseline dyspnea index), Functional 
status (forced spirometry). Interventions: Intervention-A: Written information. A leaf-
let with the correct inhalation technique for the main inhaler devices used in our 
area. Intervention-B: Intervention-A + individual training (by instructors). Follow-up: 3 
month, visits: baseline, 1 month, 3 month. Statiscal analysis: Mean, frequency, 95% 
confidence interval at baseline. Number Needed to Treat for a benefit (NNT) was cal-
culated. Intention to treat analysis. results: Predominance of males (91.4%), mean 
age 69.8 years (CI95%, 69.00-70.59); FEV1(mean)= 55.91% (IC95%, 53.62-58.2), mixed 
respiratory pattern (65.9%). Severity stage: 15.7% mild, 44.1% Moderate, 40.3% Severe. 
Pharmacological treatment: inhaled-beta2-adrenergic (88.8%); inhaled-corticosteroids 
(76.7%); inhaled-anticholinergic (70.7%); mucolitycs (19.4%); xanthine (7.3%); oral-corti-
costeroids (1.3%). BDI: grade 2. Primary outcome: better inhalation technique (p= 0.002) 
in the PPS group, NNT= 7.4 (IC95%, 4.52-20).Among the RCT cohorts: there was no differ-
ence between control and intervention A and there were statistically significative dif-
ferences between intervention B versus control (p< 0.0001), NNT= 2.44 (IC95%, 1.87-3.5) 
and versus intervention A, NNT= 2.85 (IC95%, 2.08-4.56). In the PPS cohorts: there was a 
difference (p< 0.0001) between intervention B versus intervention A, NNT= 2.33 (IC95%, 
1.5-3.2). conclusions: The performance of a correct inhalation Technique improves 
with monitor training. The patients’ preferences enhance the efficacy of intervention.
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RElationShiP BEtwEEn mEdication adhEREncE and quality of lifE in 
coPd – SyStEmatic REviEw
Ágh T.1, Inotai A.1, Bártfai Z.2, Mészáros Á3
1Syreon Research Institute, Budapest, Hungary, 2Elizabeth Teaching Hospital and Rehabilitation 
Institute Sopron, Sopron, Hungary, 3Semmelweis Univesity, Budapest, Hungary
